title: The VITAH trial VITamin D supplementation and cardiac Autonomic tone in Hemodialysis: a blinded, randomized controlled trial.
abstract: BACKGROUND
  Patients with end-stage kidney disease (ESKD) have a high rate of mortality and specifically an increased risk of sudden cardiac death (SCD). Impaired cardiac autonomic tone is associated with elevated risk of SCD. Moreover, patients with ESKD are often vitamin D deficient, which we have shown may be linked to autonomic dysfunction in humans. To date, it is not known whether vitamin D supplementation normalizes cardiac autonomic function in the high-risk ESKD population. The VITamin D supplementation and cardiac Autonomic tone in Hemodialysis (VITAH) randomized trial will determine whether intensive vitamin D supplementation therapies improve cardiac autonomic tone to a greater extent than conventional vitamin D supplementation regimens in ESKD patients requiring chronic hemodialysis.
  
  
  METHODS
  A total of 60 subjects with ESKD requiring thrice weekly chronic hemodialysis will be enrolled in this 2x2 crossover, blinded, randomized controlled trial. Following a 4-week washout period from any prior vitamin D therapy, subjects are randomized 1:1 to intensive versus standard vitamin D therapy for 6 weeks, followed by a 12-week washout period, and finally the remaining treatment arm for 6 weeks. Intensive vitamin D treatment includes alfacalcidiol (activated vitamin D) 0.25 mcg orally with each dialysis session combined with ergocalciferol (nutritional vitamin D) 50 000 IU orally once per week and placebo the remaining two dialysis days for 6 weeks. The standard vitamin D treatment includes alfacalcidiol 0.25 mcg orally combined with placebo each dialysis session per week for 6 weeks. Cardiac autonomic tone is measured via 24 h Holter monitor assessments on the first dialysis day of the week every 6 weeks throughout the study period. The primary outcome is change in the low frequency: high frequency heart rate variability (HRV) ratio during the first 12 h of the Holter recording at 6 weeks versus baseline. Secondary outcomes include additional measures of HRV. The safety of intensive versus conventional vitamin D supplementation is also assessed.
  
  
  CONCLUSIONS
  VITAH will determine whether an intensive vitamin D supplementation regimen will improve cardiac autonomic tone compared to conventional vitamin D supplementation and will assess the safety of these two supplementation regimens in ESKD patients receiving chronic hemodialysis.
  
  
  BACKGROUND
  ClinicalTrials.gov, NCT01774812.
authors.forename: Michelle C
authors.initials: MC
authors.lastname: Mann
authors.forename: Derek V
authors.initials: DV
authors.lastname: Exner
authors.forename: Brenda R
authors.initials: BR
authors.lastname: Hemmelgarn
authors.forename: David A
authors.initials: DA
authors.lastname: Hanley
authors.forename: Tanvir C
authors.initials: TC
authors.lastname: Turin
authors.forename: Jennifer M
authors.initials: JM
authors.lastname: MacRae
authors.affiliation: Department of Medicine, University of Calgary, 1403-29th St, NW, Room C210D, T2N 2 T9 Calgary, Alberta, Canada. sofia.ahmed@albertahealthservices.ca.
authors.forename: Sofia B
authors.initials: SB
authors.lastname: Ahmed
mesh_terms: D018592:Cross-Over Studies; D019587:Dietary Supplements; D004311:Double-Blind Method; D005260:Female; D005500:Follow-Up Studies; D006339:Heart Rate / Q000187:drug effects* / Q000502:physiology; D006801:Humans; D007676:Kidney Failure, Chronic / Q000175:diagnosis / Q000188:drug therapy* / Q000453:epidemiology; D008297:Male; D006435:Renal Dialysis / Q000379:methods*; D014807:Vitamin D / Q000008:administration & dosage*; D014808:Vitamin D Deficiency / Q000175:diagnosis / Q000188:drug therapy* / Q000453:epidemiology
chemical_list: D014807:Vitamin D
references.citation: J Clin Endocrinol Metab. 2012 Jul;97(7):2456-65
references.pmid: 22539586
references.citation: N Engl J Med. 2005 Jul 21;353(3):238-48
references.pmid: 16034009
references.citation: Am J Kidney Dis. 2010 May;55(5):800-12
references.pmid: 20438984
references.citation: Int J Cardiol. 2009 Jan 24;131(3):370-7
references.pmid: 18199499
references.citation: Int J Cardiol. 2014 Mar 15;172(2):506-8
references.pmid: 24502876
references.citation: N Engl J Med. 2007 Jul 19;357(3):266-81
references.pmid: 17634462
references.citation: JAMA. 2012 Feb 15;307(7):674-84
references.pmid: 22337679
references.citation: Clin Exp Hypertens. 2014;36(6):386-91
references.pmid: 24164282
references.citation: J Am Soc Nephrol. 2010 Sep;21(9):1550-9
references.pmid: 20576808
references.citation: Circulation. 2008 Jan 29;117(4):503-11
references.pmid: 18180395
references.citation: Kidney Int. 2004 Feb;65(2):661-5
references.pmid: 14717939
references.citation: Nephrol Dial Transplant. 2008 Feb;23(2):444-9
references.pmid: 18003665
references.citation: N Engl J Med. 2009 Apr 2;360(14):1395-407
references.pmid: 19332456
references.citation: Am J Kidney Dis. 2012 Jul;60(1):139-56
references.pmid: 22560832
references.citation: Eur J Immunol. 2002 Dec;32(12):3443-52
references.pmid: 12442326
references.citation: Cochrane Database Syst Rev. 2009 Oct 07;(4):CD005633
references.pmid: 19821349
references.citation: Nephrol Dial Transplant. 2008 Oct;23(10):3061-2
references.pmid: 18503010
references.citation: Am J Kidney Dis. 1998 Aug;32(2):221-9
references.pmid: 9708605
references.citation: Clin J Am Soc Nephrol. 2012 Feb;7(2):358-65
references.pmid: 22193236
references.citation: Nephrol Dial Transplant. 1999 Jun;14(6):1480-8
references.pmid: 10383012
references.citation: Nephrol Dial Transplant. 2003 Feb;18(2):318-25
references.pmid: 12543887
references.citation: Circulation. 1996 Mar 1;93(5):1043-65
references.pmid: 8598068
references.citation: Kidney Int. 2007 Oct;72(8):1004-13
references.pmid: 17687259
references.citation: Semin Dial. 2003 Mar-Apr;16(2):111-7
references.pmid: 12641874
references.citation: J Mol Cell Cardiol. 1994 Dec;26(12):1593-9
references.pmid: 7731054
references.citation: J Am Coll Cardiol. 1999 Dec;34(7):1878-83
references.pmid: 10588197
references.citation: Comput Inform Nurs. 2005 Nov-Dec;23(6):335-41
references.pmid: 16292049
references.citation: J Clin Endocrinol Metab. 2012 Apr;97(4):1146-52
references.pmid: 22442278
references.citation: J Steroid Biochem Mol Biol. 2004 May;89-90(1-5):571-3
references.pmid: 15225841
references.citation: J Mol Cell Cardiol. 2006 Aug;41(2):350-9
references.pmid: 16815434
references.citation: J Clin Endocrinol Metab. 2008 Oct;93(10):3927-35
references.pmid: 18682515
references.citation: Kidney Int Suppl. 2009 Aug;(113):S1-130
references.pmid: 19644521
references.citation: Neurology. 2010 Jun 8;74(23):1852-9
references.pmid: 20427749
references.citation: Lancet. 2011 Jun 25;377(9784):2181-92
references.pmid: 21663949
references.citation: Nephron Clin Pract. 2006;102(1):c21-9
references.pmid: 16166802
references.citation: J Am Soc Nephrol. 2014 Jan;25(1):175-86
references.pmid: 24052631
references.citation: J Clin Pharm Ther. 2002 Apr;27(2):85-92
references.pmid: 11975691
references.citation: Nutrients. 2013 Jun 10;5(6):2114-27
references.pmid: 23752493
references.citation: Nephrol Dial Transplant. 2011 Mar;26(3):1024-32
references.pmid: 20947538
references.citation: Mol Cell Endocrinol. 1991 Dec;82(2-3):229-35
references.pmid: 1665453
references.citation: Clin J Am Soc Nephrol. 2010 Oct;5(10):1821-7
references.pmid: 20616163
references.citation: Kidney Int. 1999 Jul;56(1):232-7
references.pmid: 10411697
references.citation: Mol Cell Endocrinol. 1991 May;77(1-3):67-73
references.pmid: 1816004
references.citation: Eur Heart J. 2010 Sep;31(18):2253-61
references.pmid: 20688781
references.citation: Ann Noninvasive Electrocardiol. 2005 Jan;10(1):88-101
references.pmid: 15649244
references.citation: QJM. 2005 Feb;98(2):87-95
references.pmid: 15671474
references.citation: Diabetes Care. 1997 Mar;20(3):355-61
references.pmid: 9051387